Recent blog posts
FDA Approves OncoC4's IND for SIGLEC 10 Blocker ONC-841 Against Solid Tumors
Latest Hotspot
3 min read
FDA Approves OncoC4's IND for SIGLEC 10 Blocker ONC-841 Against Solid Tumors
26 April 2024
OncoC4 Reveals FDA Approval for Investigational New Drug Application of Its Unique SIGLEC 10 Immune Checkpoint Blocker, ONC-841, Targeting Solid Tumors.
Read →
hC Bioscience Unveils Hemophilia Project and Promising Results from tRNA Anticodon Strategy
Latest Hotspot
3 min read
hC Bioscience Unveils Hemophilia Project and Promising Results from tRNA Anticodon Strategy
26 April 2024
hC Bioscience Reveals Primary Project in Hemophilia and Shares Encouraging Early Results from Innovative Protein Modification Strategy Using Engineered tRNA Anticodons.
Read →
Promising Early Results for ALTO-101, Alto Neuroscience's New Schizophrenia Drug
Latest Hotspot
3 min read
Promising Early Results for ALTO-101, Alto Neuroscience's New Schizophrenia Drug
26 April 2024
Alto Neuroscience revealed encouraging initial outcomes for ALTO-101, a new PDE4 inhibitor, aimed at treating schizophrenia.
Read →
Hanmi collaborates clinically and signs supply deal with MSD to test BH3120 along with KEYTRUDA® (pembrolizumab)
Latest Hotspot
3 min read
Hanmi collaborates clinically and signs supply deal with MSD to test BH3120 along with KEYTRUDA® (pembrolizumab)
26 April 2024
Hanmi Pharmaceutical will start a phase 1 clinical trial to evaluate the safety and effectiveness of its cancer immunotherapy, ‘BH3120’, in combination with MSD's KEYTRUDA® (pembrolizumab).
Read →
BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
Latest Hotspot
3 min read
BeiGene Secures EC Nod for Tislelizumab in Treating Non-Small Cell Lung Cancer
26 April 2024
BeiGene, Ltd. disclosed that tislelizumab has received approval from the European Commission for use in treating non-small cell lung cancer.
Read →
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
Latest Hotspot
3 min read
Initial Dosing in Phase I Glioblastoma Trial by ITM, Helmholtz Munich, and University Hospital Münster
25 April 2024
ITM, Helmholtz Munich, and University Hospital Münster Report Initial Dosing of First Participant in Phase I Research Trial for Glioblastoma.
Read →
EU Sanctions Voydeya as Supplementary Treatment for PNH with Persistent Haemolytic Anaemia
Latest Hotspot
3 min read
EU Sanctions Voydeya as Supplementary Treatment for PNH with Persistent Haemolytic Anaemia
25 April 2024
Voydeya has been sanctioned in the EU as a supplementary treatment alongside ravulizumab or eculizumab for adults with PNH who still suffer from persistent haemolytic anaemia.
Read →
The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
Latest Hotspot
3 min read
The Phase 3 LUNA 3 trial of Rilzabrutinib successfully achieved its main goal in treating immune thrombocytopenia
25 April 2024
The recent phase 3 LUNA 3 trial demonstrated that 400 mg of rilzabrutinib taken orally twice daily effectively achieved the primary goal of sustaining platelet response in adults with persistent or chronic immune thrombocytopenia.
Read →
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
Latest Hotspot
3 min read
FDA Approves ImmunityBio’s ANKTIVA® for BCG-Resistant Bladder Cancer
25 April 2024
ImmunityBio Receives FDA Nod for ANKTIVA®, a Novel IL-15 Receptor Stimulator, for Treating BCG-Resistant Non-Muscle Invasive Bladder Cancer.
Read →
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
Latest Hotspot
3 min read
Neurogene to Present Early Results on NGN-401 Gene Therapy for Rett Syndrome at ASGCT Conference
25 April 2024
Neurogene Set to Reveal NGN-401 Gene Therapy Safety Results from Early Stage Trial for Rett Syndrome during ASGCT Conference.
Read →
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
Latest Hotspot
3 min read
Adicet Bio Showcases Preclinical Readiness of ADI-270 for IND at 27th ASGCT Meeting
25 April 2024
Adicet Bio presents preclinical findings indicating IND preparedness for ADI-270 during a talk at the 27th Annual ASGCT Meeting.
Read →
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
Latest Hotspot
3 min read
ASLAN Pharmaceuticals Announces Positive Early Results from Phase 2 Eblasakimab Trial in Atopic Dermatitis Patients Previously on Dupilumab
24 April 2024
ASLAN Pharmaceuticals Reports Encouraging Preliminary Outcomes from a Phase 2 Trial of Eblasakimab in Patients with Atopic Dermatitis Previously Treated with Dupilumab.
Read →